U.S. Office REITs Stock News

Alkermes (NasdaqGS:ALKS) has begun Phase 3 clinical trials for alixorexton, its orexin 2 receptor agonist for narcolepsy type 1 and type 2. The late stage Brilliance Studies aim to evaluate alixorexton in patients with significant unmet treatment needs in sleep disorders. This marks a new development in Alkermes' pipeline beyond prior focus areas highlighted in earlier coverage. For Alkermes, known for its work in neuroscience and psychiatry, the Brilliance Studies add a new dimension to...

Jiayin Group Inc. has reported its fourth-quarter and full-year 2025 results, showing quarterly revenue of CNY 1,090.2 million and net income of CNY 100.63 million, alongside full-year revenue of CNY 6,222.19 million and net income of CNY 1,535.74 million. Alongside these results, the company increased its dividend payout framework to target around 30% of prior-year net income and completed a share repurchase of 4,600,000 shares, equal to 8.6% of its share count, signaling a stronger focus...

Core & Main (NYSE:CNM) has appointed former American Water Works CEO M. Susan Hardwick to its board, effective April 1. The company has restructured key governance roles, including a new board chair and a new audit committee chair. The longstanding executive chair has retired as part of the succession changes. Core & Main, trading at $49.4, is adjusting its leadership structure after a 3-year return of 121.8% and a 1-year return of 0.0%. The share price has seen a 2.3% decline over the past...

Ocugen (NasdaqCM:OCGN) completed enrollment and dosing early in its pivotal Phase 2/3 GARDian3 trial for OCU410ST. The trial evaluates a one time gene therapy candidate for Stargardt disease, a severe inherited retinal disorder with no approved treatments. This is Ocugen's second late stage clinical program and aligns with its stated goal to submit multiple BLAs by 2028. For readers tracking gene therapy names, Ocugen sits at the intersection of rare ophthalmology and inherited retinal...

Vera Therapeutics has appointed Jane Wright-Mitchell as its new Chief Legal Officer. Wright-Mitchell brings extensive legal, compliance, and intellectual property experience in life sciences and pharmaceuticals. The appointment adds senior leadership depth as Vera Therapeutics continues to develop its pipeline. The new Chief Legal Officer steps in at a time when Vera Therapeutics, listed as NasdaqGM:VERA, is trading at $40.23. The share price reflects a mixed return profile, with a 1.2%...

FirstSun Capital Bancorp (NasdaqGS:FSUN) has been removed from the Russell 2000 Defensive Index. The company has also been dropped from the Russell 2500 Defensive, Russell 2500 Value-Defensive, and Russell 2000 Value-Defensive indices. This index reclassification affects how some passive and rules based funds may hold or view the stock. FirstSun Capital Bancorp, the holding company for FirstBank, operates as a regional banking platform focused on commercial and consumer financial services...

In the last week, the United States market has stayed flat but is up 16% over the past year, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for sustained revenue and earnings expansion in alignment with these broader market trends.

Over the last 7 days, the United States market has remained flat, yet it is up 16% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying stocks that are trading at a discount can offer potential opportunities for investors seeking value in a growing market.

In the last week, the United States market has stayed flat, yet it has risen by 16% over the past year with expectations of a 15% annual earnings growth in the coming years. In this context, identifying growth companies with high insider ownership can be advantageous as they often align management interests with shareholder value and may capitalize on favorable market conditions.

The market remained flat over the last week, but it is up 16% over the past year, with earnings expected to grow by 15% annually in the coming years. For those interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value and potential for growth. By focusing on stocks with strong financial foundations, investors may find opportunities that combine stability with promising prospects.

Over the last 7 days, the United States market has remained flat, yet it boasts a notable 16% rise over the past year with earnings forecasted to grow by 15% annually. In such a dynamic environment, discovering promising small-cap stocks that have potential for growth can be key to capitalizing on these positive trends.

With the business potentially at an important milestone, we thought we'd take a closer look at Iterum Therapeutics...

We can readily understand why investors are attracted to unprofitable companies. For example, Annexon ( NASDAQ:ANNX...

Creative Medical Technology Holdings, Inc. ( NASDAQ:CELZ ) is possibly approaching a major achievement in its business...

Potential LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders may wish to note that the President, Evert...

The market seemed underwhelmed by the solid earnings posted by Adobe Inc. ( NASDAQ:ADBE ) recently. Along with the...

Market forces rained on the parade of MeiraGTx Holdings plc ( NASDAQ:MGTX ) shareholders today, when the analysts...

Wondering if National Health Investors is priced fairly today or if the current share price leaves some room on the table? This overview walks through what the recent numbers may be saying about value. The stock closed at US$80.86, with returns of 5.2% year to date and 14.2% over the last year, while the past 7 and 30 days have seen declines of 2.1% and 3.8% respectively. Recent coverage has focused on how real estate investment trusts are responding to changing conditions in healthcare...

Sangamo Therapeutics (SGMO) closed out FY 2025 with Q4 revenue of US$14.2 million and a basic EPS loss of US$0.11, as net income excluding extra items came in at a loss of US$37.4 million. On a trailing twelve month basis, revenue was US$39.6 million with a basic EPS loss of US$0.44 and a net loss of US$122.9 million. The company has seen quarterly revenue range from US$0.6 million to US$49.4 million across the last six reported periods, with basic EPS moving between a loss of US$0.14 and a...

DeFi Development (DFDV) just wrapped up FY 2025 with Q4 total revenue of US$4.5 million and a basic EPS loss of US$5.48, while trailing twelve month revenue sat at US$11.4 million against a basic EPS loss of US$4.00. Over the past six reported quarters, the company has seen quarterly revenue move from US$0.62 million in Q4 2024 to US$4.5 million in Q4 2025, with EPS swinging between a loss of US$0.05 and a profit of US$2.41 before landing back in loss-making territory. This leaves investors...

Rezolve AI (RZLV) has just put fresh FY 2025 numbers on the table, with second half revenue of about US$40.5 million and a basic EPS loss of US$0.14, backed by trailing twelve month revenue of roughly US$46.8 million and a basic EPS loss of US$0.38. The company has seen revenue move from just US$0.1 million in the second half of FY 2024 to US$6.3 million in the first half of FY 2025 and then to US$40.5 million in the latest half, while basic EPS losses shifted from US$0.98 to US$0.25 and then...

If you are wondering whether Buckle at around US$50.36 offers solid value or is pricing in too much optimism, this breakdown will help you frame that question clearly. The stock has had a mixed short term patch, with a 0.6% return over the last week, a 6.0% decline over the past month, and a 6.5% decline year to date, as well as a 42.9% return over the last year and 84.3% and 112.4% returns over the past 3 and 5 years. Recent coverage has focused on Buckle in the context of broader retail...

First Keystone (FKYS) just wrapped up FY 2025 with fourth quarter revenue of US$7.8 million and a basic EPS loss of US$0.10, while the trailing twelve months show total revenue of US$40.3 million and EPS of US$0.99. Over recent periods the company has seen quarterly revenue move from US$10.4 million in Q4 2024 to US$11.5 million in Q2 2025 before landing at US$7.8 million in Q4 2025, with basic EPS shifting from US$0.37 in Q4 2024 to US$0.47 in Q2 2025 before slipping into a small loss in the...

Endava (NYSE:DAVA) has just turned in a mixed Q2 2026 scorecard, with revenue of £184.1 million, a basic EPS loss of £0.13 and net income loss of £6.9 million, set against a trailing twelve month picture that shows £743.9 million of revenue, a small EPS loss of £0.05 and a net income loss of £2.9 million. Over the past few quarters, revenue has moved from £195.6 million and EPS of £0.12 in Q2 2025 to £184.1 million and EPS of a £0.13 loss in Q2 2026, while quarterly net income shifted from a...